Evaluation of demographic, clinical, and aetiological data of patients admitted to cardiology clinics and diagnosed with left ventricular hypertrophy in Turkish population (LVH-TR)

References

• Lorell BH, Carabello BA. Left ventricular hypertrophy: pathogenesis, detection, and prognosis. Circulation 2000;102(4):470–479.
   PubMed Web of Science ®Google Scholar
• Bornstein AB, Rao SS, Marwaha K. Left ventricular hypertrophy. StatPearls; 2022. Available from: https://www.ncbi.nlm.nih.gov/books/NBK557534/.
   Google Scholar
• Baptista A, Magalhães P, Leão S, et al. Screening for Fabry disease in left ventricular hypertrophy: documentation of a novel mutation. Arq Bras Cardiol. 2015;105(2):139–144.
   PubMed Web of Science ®Google Scholar
• Coelho T, Maurer MS, Suhr OB. THAOS—the transthyretin amyloidosis outcomes survey: initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis. Curr Med Res Opin. 2013;29(1):63–76.
   PubMed Web of Science ®Google Scholar
• Menezes Fernandes R, Azevedo O, Cordeiro F, et al. Left ventricular hypertrophy secondary to Fabry disease: mechanical dispersion and arrhythmic burden. Eur Heart J. 2021;42(Supplement_1):724–1791.
   Google Scholar
• Linhart A, Germain DP, Olivotto I, et al. An expert consensus document on the management of cardiovascular manifestations of Fabry disease. Eur J Heart Fail. 2020;22(7):1076–1096.
   PubMed Web of Science ®Google Scholar
• Reuser AJ, Verheijen FW, Bali D, et al. The use of dried blood spot samples in the diagnosis of lysosomal storage disorders—current status and perspectives. Mol Genet Metab. 2011;104(1–2):144–148.
   PubMed Web of Science ®Google Scholar
• Linthorst GE, Bouwman MG, Wijburg FA, et al. Screening for Fabry disease in high-risk populations: a systematic review. J Med Genet. 2010;47(4):217–222.
   PubMed Web of Science ®Google Scholar
• Palecek T, Honzikova J, Poupetova H, et al. Prevalence of Fabry disease in male patients with unexplained left ventricular hypertrophy in primary cardiology practice: prospective Fabry cardiomyopathy screening study (FACSS). J Inherit Metab Dis. 2014;37(3):455–460.
   PubMed Web of Science ®Google Scholar
• Chimenti C, Pieroni M, Morgante E, et al. Prevalence of Fabry disease in female patients with late-onset hypertrophic cardiomyopathy. Circulation 2004;110(9):1047–1053.
   PubMed Web of Science ®Google Scholar
• Favalli V, Disabella E, Molinaro M, et al. Genetic screening of Anderson–Fabry disease in probands referred from multispecialty clinics. J Am Coll Cardiol. 2016;68(10):1037–1050.
   PubMed Web of Science ®Google Scholar
• Serra W, Marziliano N. Role of cardiac imaging in Anderson–Fabry cardiomyopathy. Cardiovasc Ultrasound 2019;17(1):1.
   PubMed Web of Science ®Google Scholar
• Militaru S, Jurcuţ R, Adam R, et al. Echocardiographic features of Fabry cardiomyopathy—comparison with hypertrophy-matched sarcomeric hypertrophic cardiomyopathy. Echocardiography 2019;36(11):2041–2049.
   PubMed Web of Science ®Google Scholar
• Barman HA, Özcan S, Atıcı A, et al. Ratio of Fabry disease in patients with idiopathic left ventricular hypertrophy: a single-center study in Turkey. Anatol J Cardiol. 2020;23(2):79–85.
   PubMed Web of Science ®Google Scholar
• Zada M, Lo Q, Trivedi SJ, et al. Electrocardiographic characteristics and their correlation with echocardiographic alterations in Fabry disease. JCDD 2022;9(1):11.
   Web of Science ®Google Scholar
• Namdar M. Electrocardiographic changes and arrhythmia in Fabry disease. Front Cardiovasc Med. 2016;3:7.
   PubMedGoogle Scholar
• Pieroni M, Moon JC, Arbustini E, et al. Cardiac involvement in Fabry disease: JACC review topic of the week. J Am Coll Cardiol. 2021;77(7):922–936.
   PubMed Web of Science ®Google Scholar
• González-López E, Gallego-Delgado M, Guzzo-Merello G, et al. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J. 2015;36(38):2585–2594.
   PubMed Web of Science ®Google Scholar
• Melero Polo J, Roteta Unceta-Barrenechea A, Revilla Martí P, et al. Echocardiographic markers of cardiac amyloidosis in patients with heart failure and left ventricular hypertrophy. Cardiol J. 2021. DOI:10.5603/CJ.a2021.0085
   PubMed Web of Science ®Google Scholar
• From AM, Maleszewski JJ, Rihal CS. Current status of endomyocardial biopsy. Mayo Clin Proc. 2011;86(11):1095–1102.
   PubMed Web of Science ®Google Scholar
• Maurer MS, Elliott P, Comenzo R, et al. Addressing common questions encountered in the diagnosis and management of cardiac amyloidosis. Circulation 2017;135(14):1357–1377.
   PubMed Web of Science ®Google Scholar
• Nakao Y, Saito M, Inoue K, et al. Cardiac amyloidosis screening using a relative apical sparing pattern in patients with left ventricular hypertrophy. Cardiovasc Ultrasound 2021;19(1):30.
   PubMed Web of Science ®Google Scholar
• Falk RH. Pondering the prognosis and pathology of cardiac amyloidosis: answers breed questions. JACC Cardiovasc Imaging 2016;9(2):139–141.
   PubMed Web of Science ®Google Scholar
• Cariou E, Bennani Smires Y, Victor G, On behalf of the Toulouse Amyloidosis Research Network Orators, et al. Diagnostic score for the detection of cardiac amyloidosis in patients with left ventricular hypertrophy and impact on prognosis. Amyloid 2017;24(2):101–109.
   PubMed Web of Science ®Google Scholar
• Levy D, Garrison RJ, Savage DD, et al. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med. 1990;322(22):1561–1566.
   PubMed Web of Science ®Google Scholar
• Giamouzis G, Dimos A, Xanthopoulos A, et al. Left ventricular hypertrophy and sudden cardiac death. Heart Fail Rev. 2022;27(2):711–724.
   PubMed Web of Science ®Google Scholar
• Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2015;28(1):1–39.e14.
   PubMed Web of Science ®Google Scholar
• Williams B, Mancia G, Spiering W, ESC Scientific Document Group, et al. 2018 ESC/ESH guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021–3104.
   PubMed Web of Science ®Google Scholar
• Kayıkçıoğlu M, Şimşek E, Kalkan Uçar S, et al. Fabry disease: an overlooked diagnosis in adult cardiac patients. Turk Kardiyol Dern Ars. 2017;45(6):549–555.
   PubMed Web of Science ®Google Scholar
• Wang SX, Xue H, Zou YB, et al. Prevalence and risk factors for left ventricular hypertrophy and left ventricular geometric abnormality in the patients with hypertension among Han Chinese. Chin Med J. 2012;125(1):21–26.
   PubMed Web of Science ®Google Scholar
• Yousef Z, Elliott PM, Cecchi F, et al. Left ventricular hypertrophy in Fabry disease: a practical approach to diagnosis. Eur Heart J. 2013;34(11):802–808.
   PubMed Web of Science ®Google Scholar
• Laney DA, Bennett RL, Clarke V, et al. Fabry disease practice guidelines: recommendations of the National Society of Genetic Counselors. J Genet Couns. 2013;22(5):555–564.
   PubMed Web of Science ®Google Scholar
• Maurer MS, Bokhari S, Damy T, et al. Expert consensus recommendations for the suspicion and diagnosis of transthyretin cardiac amyloidosis. Circ Heart Fail. 2019;12(9):e006075.
   PubMed Web of Science ®Google Scholar
• Garcia-Pavia P, Rapezzi C, Adler Y, et al. Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC working group on myocardial and pericardial diseases. Eur Heart J. 2021;42(16):1554–1568.
   PubMed Web of Science ®Google Scholar
• Kannel WB, Dannenberg AL, Levy D. Population implications of electrocardiographic left ventricular hypertrophy. Am J Cardiol. 1987;60(17):85–93.
   PubMed Web of Science ®Google Scholar
• Artham SM, Lavie CJ, Milani RV, et al. Clinical impact of left ventricular hypertrophy and implications for regression. Prog Cardiovasc Dis. 2009;52(2):153–167.
   PubMed Web of Science ®Google Scholar
• Desai CS, Ning H, Lloyd-Jones DM. Competing cardiovascular outcomes associated with electrocardiographic left ventricular hypertrophy: the atherosclerosis risk in communities study. Heart 2012;98(4):330–334.
   PubMed Web of Science ®Google Scholar
• Eguchi K, Boden-Albala B, Jin Z, et al. Association between diabetes mellitus and left ventricular hypertrophy in a multiethnic population. Am J Cardiol. 2008;101(12):1787–1791.
   PubMed Web of Science ®Google Scholar
• Maron BJ, Gardin J, Flack JM, et al. Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA study. Coronary artery risk development in (young) adults. Circulation 1995;92(4):785–789.
   PubMed Web of Science ®Google Scholar
• Terryn W, Deschoenmakere G, De Keyser J, et al. Prevalence of Fabry disease in a predominantly hypertensive population with left ventricular hypertrophy. Int J Cardiol. 2013;167(6):2555–2560.
   PubMed Web of Science ®Google Scholar
• Kubo T, Ochi Y, Baba Y, et al. Prevalence and clinical features of Fabry disease in Japanese male patients with diagnosis of hypertrophic cardiomyopathy. J Cardiol. 2017;69(1):302–307.
   PubMed Web of Science ®Google Scholar
• Mohammed SF, Mirzoyev SA, Edwards WD, et al. Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction. JACC Heart Fail. 2014;2(2):113–122.
   PubMed Web of Science ®Google Scholar
• Beneyto M, Cariou E, Brunel J, et al. Tip of the iceberg: a tertiary care centre retrospective study of left ventricular hypertrophy aetiologies. Open Heart 2021;8(1):e001462.
   PubMed Web of Science ®Google Scholar
• Lee DH, Qiu WJ, Lee J, et al. Hypertrophic cardiomyopathy in Pompe disease is not limited to the classic infantile-onset phenotype. JIMD Rep. 2014;17:71–75.
   PubMedGoogle Scholar
• Cheng Z, Cui Q, Tian Z, et al. Danon disease as a cause of concentric left ventricular hypertrophy in patients who underwent endomyocardial biopsy. Eur Heart J. 2012;33(5):649–656.
   PubMed Web of Science ®Google Scholar